tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Chris Shibutani, 84 are a BUY (56.38%), 60 are a HOLD (40.27%), 5 are a SELL (3.36%).
Analyst Chris Shibutani, carries an average stock price target met ratio of 60.4% that have a potential upside of 18.16% achieved within 180 days. Previously, Chris Shibutani worked at GOLDMAN SACHS.
Chris Shibutani’s has documented 297 price targets and ratings displayed on 35 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ERAS, Erasca at 21-Mar-2025.
Analyst best performing recommendations are on RXDX (PROMETHEUS BIOSCIENCES).
The best stock recommendation documented was for RXDX (PROMETHEUS BIOSCIENCES) at 12/7/2022. The price target of $117 was fulfilled within 1 day with a profit of $21.2 (22.13%) receiving and performance score of 221.29.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
$35
$4.74 (15.66%)
$34
1 months 14 days ago
(08-Sep-2025)
8/9 (88.89%)
$7.15 (25.67%)
112
Hold
$46
$15.74 (52.02%)
$46
1 months 14 days ago
(08-Sep-2025)
19/25 (76%)
$18.15 (65.17%)
295
Buy
$45
$14.74 (48.71%)
$45
2 months 24 days ago
(28-Jul-2025)
0/3 (0%)
$18 (66.67%)
Buy
$42
$11.74 (38.80%)
$38
4 months 6 days ago
(16-Jun-2025)
2/4 (50%)
$12.23 (41.08%)
86
Buy
$41
$10.74 (35.49%)
$38
5 months 21 days ago
(01-May-2025)
0/2 (0%)
$9.22 (29.01%)
What Year was the first public recommendation made by Chris Shibutani?
